Tislelizumab by BeiGene for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Tislelizumab is under clinical development by BeiGene and currently in Pre-Registration for Esophageal Squamous Cell Carcinoma (ESCC).

Takeda reveals PhII fail for rare genetic condition, looks to new product pipeline to bolster growth

Takeda’s Phase II program in a rare hereditary disease called metachromatic leukodystrophy (MLD) is “likely to be discontinued” after failing its primary and secondary endpoints,

July 28, 2023

Did the gut microbiome composition of infants change during the COVID-19 pandemic?

A recent study compared infant gut microbiome composition before and during the COVID-19 pandemic.

August 21, 2023

DPI-125 by DMK Pharmaceuticals for Opium (Opioid) Addiction: Likelihood of Approval

DPI-125 is under clinical development by DMK Pharmaceuticals and currently in Phase I for Opium (Opioid) Addiction.

July 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.